Core Viewpoint - Huajian Medical (01931) has seen a significant stock price increase of over 16% following the announcement of a successful multi-billion yuan revolving loan obtained by its subsidiary, Weishida, from a banking syndicate led by East Asia Bank's Shanghai branch [1] Group 1: Financial Developments - The revolving loan involves participation from seven financial institutions, including Mitsui Sumitomo, Shengjing Bank, and Busan Bank of Korea [1] - The stock price rose by 16.31%, reaching HKD 4.35, with a trading volume of HKD 15.16 million [1] Group 2: Strategic Initiatives - On July 17, the company announced the establishment of the "IVDNewCo Exchange," a Web3 ecosystem focused on high-tech medical innovation assets, along with the issuance of a proprietary stablecoin, IVD Dollar (IVDD) [1] - On July 20, Huajian Medical registered a wholly-owned subsidiary, IVD GROUP INC., in New York, and initiated the application for stablecoin licenses with the SEC and CFTC [1] Group 3: Market Positioning - The "IVDNewCo Exchange" aims to address significant pain points in the pharmaceutical industry, where new drug development typically takes 10 years and 80% of funding is spent in clinical stages, while ordinary investors are often excluded [1] - The company’s strategy involves converting high-value medical assets, such as phase II clinical ADC drugs and gene therapy patents, into tradable digital certificates through RWA technology [1] - Huajian Medical aims to become the "Nasdaq + Uniswap" of the medical RWA sector, ensuring compliance while achieving decentralized liquidity, leveraging its first-mover advantage in a niche market [1]

智通财经APP获悉，华检医疗(01931)尾盘涨超16%，截至发稿，涨16.31%，报4.35港元，成交额1516.12 万港元。 消息面上，7月29日，华检医疗发布公告称，子公司威士达成功获得一笔数亿元循环贷款。该银团贷款 由东亚银行上海分行牵头，三井住友、盛京银行、韩国釜山银行等7家金融机构组成的银团共同参与。 值得注意的是，7月17日，公司宣布构建全球首个聚焦医疗创新药高科技资产的"NewCo+RWA"Web3交 易所生态，命名为"IVDNewCo Exchange"，并配套发行专有稳定币IVD Dollar（IVDD）；7月20日，华 检医疗在美国纽约注册成立全资子公司IVD GROUP INC.，同步启动向SEC、CFTC提交稳定币牌照申请 智通财经APP在《稳定币条例生效前夜 华检医疗(01931)收获三张实际"信任票"》中指出，公司构建名 为"IVDNewCo Exchange"的Web3交易所生态，直击医药行业痛点：一款新药研发需10年，80%资金砸 在临床阶段，普通投资者却被拒之门外。华检医疗的解决方案是将高价值医疗资产——如Ⅱ期临床的 ADC药物、基因疗法专利——通过RWA技术转化为可分割 ...